Aromatase inhibitors: Changing the face of endocrine therapy for breast cancer

Breast Disease

Volumn 24, Issue 1, 2005, Pages 107-117

  Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CELECOXIB; EXEMESTANE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LETROZOLE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGESTROL ACETATE; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE; TRIACYLGLYCEROL;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TOLERABILITY; EARLY CANCER; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; OVERALL SURVIVAL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VAGINA BLEEDING; VAGINA DISCHARGE;

EID: 33747354141     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/bd-2006-24109     Document Type: Article

References (48)

1. Early Breast Cancer Trialists' Collaborative Group, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials, Lancet 365 (2005), 1687-1717.
2. B. Fisher, J. Dignam, J. Bryant, A. DeCillis, D.L. Wickerham, N. Wolmark, J. Costantino, C. Redmond, E.R. Fisher, D.M. Bowman, L. Deschenes, N.V. Dimitrov, R.G. Margolese, A. Robidoux, H. Shibata, J. Terz, A.H. Paterson, M.I. Feldman, W. Farrar, J. Evans and H.L. Lickley, Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors, J Natl Cancer Inst 88 (1996), 1529-1542.
3. D.K. Wysowski, S. Honig and J. Beitz, Uterine sarcoma associated with tamoxifen use, N Engl J Med 346 (2002), 1832-1833.
4. R.J. Santen, T.J. Worgul, A. Lipton, H. Harvey, A. Boucher, E. Samojlik and S.A. Wells, Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma, Ann Intern Med 96 (1982), 94-101.
5. B. Thürlimann, M. Castiglione, S.F. Hsu-Schmitz, F. Cavalli, H. Bonnefoi, M.F. Fey, R. Morant, T. Lohnert and A. Goldhirsch, Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK), Eur J Cancer 33 (1997), 1017-1024.
6. L.R. Wiseman and D. McTavish, Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer, Drugs 45 (1993), 66-84.
7. A. Buzdar, J. Douma, N. Davidson, R. Elledge, M. Morgan, R. Smith, L. Porter, J. Nabholtz, X. Xiang and C. Brady, Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate, J Clin Oncol 19 (2001), 3357-3366.
8. A.U. Buzdar, S.E. Jones, C.L. Vogel, J. Wolter, P. Plourde and A. Webster, A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group, Cancer 79 (1997), 730-739.
9. A.U. Buzdar, W. Jonat, A. Howell, S.E. Jones, C.P. Blomqvist, C.L. Vogel, W. Eiermann, J.M. Wolter, M. Steinberg, A. Webster and D. Lee, Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group, Cancer 83 (1998), 1142-1152.
10. P. Dombernowsky, I. Smith, G. Falkson, R. Leonard, L. Panasci, J. Bellmunt, W. Bezwoda, G. Gardin, A. Gudgeon, M. Morgan, A. Fornasiero, W. Hoffmann, J. Michel, T. Hatschek, T. Tjabbes, H.A. Chaudri, U. Hornberger and P.F. Trunet, Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate, J Clin Oncol 16 (1998), 453-461.
11. W. Jonat, A. Howell, C. Blomqvist, W. Eiermann, G. Winblad, C. Tyrrell, L. Mauriac, H. Roche, S. Lundgren, R. Hellmund and M. Azab, A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer, Eur J Cancer 32A (1996), 404-412.
12. M. Kaufmann, E. Bajetta, L.Y. Dirix, L.E. Fein, S.E. Jones, N. Zilembo, J.L. Dugardyn, C. Nasurdi, R.G. Mennel, J. Cervek, C. Fowst, A. Polli, E. di Salle, A. Arkhipov, G. Piscitelli, L.L. Miller and G. Massimini, Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. The Exemestane Study Group, J Clin Oncol 18 (2000), 1399-1411.
13. J. Bonneterre, B. Thürlimann, J.F. Robertson, M. Krzakowski, L. Mauriac, P. Koralewski, I. Vergote, A. Webster, M. Steinberg and M. von Euler, Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study, J Clin Oncol 18 (2000), 3748-3757.
14. J. Bonneterre, A. Buzdar, J.M. Nabholtz, J.F. Robertson, B. Thürlimann, M. von Euler, T. Sahmoud, A. Webster, M. Steinberg, Arimidex Writing Committee and Investigators Committee Members, Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma, Cancer 92 (2001), 2247-2258.
15. A. Milla-Santos, L. Milla, J. Portella, L. Rallo, M. Pons, E. Rodes, J. Casanovas and M. Puig-Gali, Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III study, Am J Clin Oncol 26 (2003), 317-322.
16. H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez-Carrion, C. Boni, A. Monnier, J. Apffelstaedt, R. Smith, H.P. Sleeboom, F. Janicke, A. Pluzanska, M. Dank, D. Becquart, P.P. Bapsy, E. Salminen, R. Snyder, M. Lassus, J.A. Verbeek, B. Staffler, H.A. Chaudri-Ross and M. Dugan, Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group, J Clin Oncol 19 (2001), 2596-2606.
17. H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez-Carrion, C. Boni, A. Monnier, J. Apffelstaedt, R. Smith, H.P. Sleeboom, F. Jaenicke, A. Pluzanska, M. Dank, D. Becquart, P.P. Bapsy, E. Salminen, R. Snyder, H. Chaudri-Ross, R. Lang, P. Wyld and A. Bhatnagar, Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group, J Clin Oncol 21 (2003), 2101-2109.
18. J.M. Nabholtz, A. Buzdar, M. Pollak, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster and M. von Euler, Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group, J Clin Oncol 18 (2000), 3758-3767.
19. J.M. Nabholtz, J. Bonneterre, A. Buzdar, J.F.R. Robertson, B. Thürlimann and for the Arimidex Writing Committee on behalf of the Investigators, Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Survival analysis and updated safety results, Eur J Cancer 39 (2003), 1684-1689.
20. R. Paridaens, P. Therasse, L. Dirix, L. Beex, M.J. Piccart, D. Cameron, T. Cufer, K. Roosendael, M. Nooy and M.R. Mattiaci, First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) - EORTC 10951 in collaboration with the exemestane working group and NCIC, Eur J. Cancer 2(Suppl) [3] (2004), 126.
21. Paridaens, R. Final results of a randomized Phase III trial comparing exemestane with tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. http://www.asco.org/ ac/1,1003,_12-002511-00_18-002600_19-009893,00.asp. 2004. 30-9-2005.
22. B. Thurlimann, A. Kesaviah, H. Mouridsen, L. Mauriac, J.F. Forbes, R. Paridaens, M. Castiglione-Gertsch, R.D. Gelber, I. Smith and A. Goldhirsch, BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer, J. Clin. Oncol. (Meeting Abstracts) 23 (2005), 6s. Abstract.
23. ATAC Trialists' Group, Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer, Lancet 365 (2005), 60-62.
24. R. Jakesz, M. Kaufmann, M. Gnant, W. Jonat, M. Mittleboek, R. Greil, C. Tausch, J. Hilfrich, W. Kwasny, H. Samonigg and on behalf of the ABCSG and the GABG, Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial, Breast Cancer Research and Treatment 88 (Suppl 1) (2004), S7.
25. F. Boccardo, A. Rubagotti, M. Puntoni, P. Guglielmini, D. Amoroso, A. Fini, G. Paladini, M. Mesiti, D. Romeo, M. Rinaldini, S. Scali, M. Porpiglia, C. Benedetto, N. Restuccia, F. Buzzi, R. Franchi, B. Massida, V. Distante, D. Amadori and P. Sismondi, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial, J Clin Oncol 23 (2005), 5138-5147.
26. R.C. Coombes, E. Hall, L.J. Gibson, R. Paridaens, J. Jassem, T. Delozier, S.E. Jones, I. Alvarez, G. Bertelli, O. Ortmann, A.S. Coates, E. Bajetta, D. Dodwell, R.E. Coleman, L.J. Fallowfield, E. Mickiewicz, J. Andersen, P.E. Lonning, G. Cocconi, A. Stewart, N. Stuart, C.F. Snowdon, M. Carpentieri, G. Massimini and J.M. Bliss, A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer, N Engl J Med 350 (2004), 1081-1092.
27. B. Fisher, J. Dignam, J. Bryant and N. Wolmark, Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial, J Natl Cancer Inst 93 (2001), 684-690.
28. P.E. Goss, J.N. Ingle, S. Martino, N.J. Robert, H.B. Muss, M.J. Piccart, M. Castiglione, D. Tu, L.E. Shepherd, K.I. Pritchard, R.B. Livingston, N.E. Davidson, L. Norton, E.A. Perez, J.S. Abrams, P. Therasse, M.J. Palmer and J.L. Pater, A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer, N Engl J Med 349 (2003), 1793-1802.
29. R. Jakesz, H. Samonigg, R. Greil, M. Gnant, M. Schmid, W. Kwasny, E. Kubista, B. Mlineritsch, C. Tausch, M. Stierer and on behalf of the ABCSG, Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a), J. Clin. Oncol. (Meeting Abstracts) 23(16s part I of II) (2005), 10s.
30. L. Cataliotti, A. Buzdar, S. Noguchi and J. Bines, Efficacy of pre-operative Arimidex (anastrozole) compared with tamoxifen (PROACT) as neoadjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer, Eur. J. Cancer Suppl. 2(3) (2004), 69.
31. I.E. Smith, M. Dowsett, S.R. Ebbs, J.M. Dixon, A. Skene, J.U. Blohmer, S.E. Ashley, S. Francis, I. Boeddinghaus and G. Walsh, Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) multicenter double-blind randomized trial, J Clin Oncol 23 (2005), 5108-5116.
32. I. Smith and L. Cataliotti, Anastrozole versus tamoxifen as neoadjuvant therapy for estrogen receptor-positive breast cancer in postmenopausal women: The IMPACT and PROACT trials, Eur. J. Cancer Suppl. 2(3) (2004), 69.
33. W. Eiermann, S. Paepke, J. Appfelstaedt, A. Llombart-Cussac, J. Eremin, J. Vinholes, L. Mauriac, M. Ellis, M. Lassus, H.A. Chaudri-Ross, M. Dugan, M. Borgs and Letrozole Neo-Adjuvant Breast Cancer Study Group, Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study, Ann Oncol 12 (2001), 1527-1532.
34. R.C. Coombes, E. Hall, C.F. Snowdon, J.M. Bliss and on behalf of the Intergroup Exemestane Study (IES), The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen - updated survival analysis, Breast Cancer Research and Treatment 88(Suppl 1) (2004), S7.
35. M.S. Elisaf, E.T. Bairaktari, C. Nicolaides, B. Kakaidi, C.S. Tzallas, A. Katsaraki and N.A. Pavlidis, Effect of letrozole on the lipid profile in postmenopausal women with breast cancer, Eur J Cancer 37 (2001), 1510-1513.
36. K.M. Wasan, P.E. Goss, P.H. Pritchard, L. Shepherd, M.J. Palmer, S. Liu, D. Tu, J.N. Ingle, M. Heath, D. Deangelis and E.A. Perez, The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L), Ann Oncol 16 (2005), 707-715.
37. T. Engan, J. Krane, D.C. Johannessen, P.E. Lønning and S. Kvinnsland, Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy, Breast Cancer Research and Treatment 36 (1995), 287-297.
38. C. Lohrisch, R. Paridaens, L.Y. Dirix, L. Beex, M. Nooij, D. Cameron, L. Biganzoli, T. Cufer, C. Yague, L. Duchateau, J.P. Lobelle and M. Piccart, No adverse impact on serum lipids of the irreversible aromatase inactivator, Aromasin [exemestane (E)] in 1st-line treatment of metastatic breast cancer (MBC): Companion study to a European Organization of Research and Treatment of Cancer (Breast Group) Trial with Pharmacia Upjohn, Proceedings of the American Society of Clinical Oncology 20 (2001), 43a.
39. J. Dewar, J.-M.A. Nabholtz, J. Bonneterre, A. Buzdar, J.F.R. Robertson, B. Thurlimann and G. Clack, The effect of anastrozole (Arimidex™) on serum lipids - data from a randomized comparison of anastrozole (AN) vs Tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC), Breast Cancer Research and Treatment 64 (Suppl) (2000), S51.
40. A. Buzdar, J.F.R. Robertson, W. Eiermann and J.M. Nabholtz, An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole and exemestane, Cancer 95 (2002), 2006-2016.
41. Early Breast Cancer Trialists' Collaborative Group, Tamoxifen for early breast cancer: An overview of the randomised trials, Lancet 351 (1998), 1451-1467.
42. T. Saphner, D.C. Tormey and R. Gray, Annual hazard rates of recurrence for breast cancer after primary therapy, J Clin Oncol 14 (1996), 2738-2746.
43. J. Houghton and on behalf of the ATAC Trialists' Group, Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: Updated data from the ATAC ('Arimidex', Alone or in Combination) Trial, J. Clin. Oncol. (Meeting Abstracts) 23(16S part I of II) (2005), 24s.
44. J. Cuzick, P. Sasieni and A. Howell, A model comparing initial use of an aromatase inhibitor with sequencing after tamoxifen in hormone receptor-positive postmenopausal women, American Society of Clinical Oncology Annual Meeting 658 (13-17 May 2005).
45. R.S. Punglia, K.M. Kuntz, E.P. Winer, J.C. Weeks and H.J. Burstein, Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis, J Clin Oncol 23 (2005), 5178-5187.
46. E.P. Winer, C. Hudis, H.J. Burstein, A.C. Wolff, K.I. Pritchard, J.N. Ingle, R.T. Chlebowski, R. Gelber, S.B. Edge, J. Gralow, M.A. Cobleigh, E.P. Mamounas, L.J. Goldstein, T.J. Whelan, T.J. Powles, J. Bryant, C. Perkins, J. Perotti, S. Braun, A.S. Langer, G.P. Browman and M.R. Somerfield, American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor - positive breast cancer: status report 2004, J Clin Oncol 23 (2005), 619-629.
47. National Comprehensive Cancer Network. NCCN practice guidelines in oncology v.1.2005: Breast cancer. http://www.nccn.org, 2005. 12-7-2005.
48. A. Goldhirsch, J.H. Glick, R.D. Gelber, A.S. Coates, B. Thurlimann and H.J. Senn, Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005, Ann Oncol 16 (2005), 1569-1583.